Merck & Co., Inc. (ETR: 6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 238.11B |
| Revenue (ttm) | 56.64B |
| Net Income (ttm) | 10.89B |
| Shares Out | n/a |
| EPS (ttm) | 4.29 |
| PE Ratio | 21.86 |
| Forward PE | n/a |
| Dividend | 2.89 (3.04%) |
| Ex-Dividend Date | Dec 16, 2024 |
| Volume | 538 |
| Open | 95.40 |
| Previous Close | 95.50 |
| Day's Range | 94.80 - 95.40 |
| 52-Week Range | 89.60 - 125.60 |
| Beta | 0.40 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 4, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv... [Read more]
Financial Performance
In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.
Financial numbers in USD Financial StatementsNews
Merck & Co Inc (MRK) Secures Global License for Innovative Cancer Therapy LM-299
Merck & Co Inc (MRK) Secures Global License for Innovative Cancer Therapy LM-299
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299, a novel investigational PD-1/VEGF bispecific ...
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the closing of the exclusive global license agreement for LM-299, a novel invest...
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials
On Thursday, Merck & Co Inc (NYSE: MRK) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection . The trials i...
Stock Of The Day: Where Does The Merck Downtrend End?
Shares of Merck & Co., Inc. (NYSE: MRK) are trading flat on Thursday, but remain in a downtrend. If the stock eventually reaches levels around $95.00, there is a good chance it reverses and heads hig...
Stock Of The Day: Where Does The Merck Downtrend End?
Shares of Merck & Co., Inc. MRK are trading flat on Thursday, but remain in a downtrend.
Personalis stock rallies 25% amid $50M Merck investment
Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time
Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my analysis of MRK stock.
Merck posts mixed late-stage trial results for HIV treatment
Merck (MRK) stock in focus as company reports mixed results in Phase 3 trials for HIV therapy islatravir in combination with doravirine. Read more here.
Merck's HIV treatment meets main goal of two late-stage studies
Merck said on Thursday its experimental drug combination to treat some adults with HIV-1 infection met the main goal of two late-stage studies.
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug, single-tabl...
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Topline Results from Phase 3 Trials Evaluating Once-Daily, Oral Doravirine/Islatravir for the Treatment of Adults with HIV-1 Infection.
What's Going On With Viking Therapeutics Stock On Wednesday?
On Wednesday, Merck & Co Inc (NYSE: MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral s...
Merck Acquires Potential Weight Loss Drug for $2 Billion
Merck Acquires Potential Weight Loss Drug for $2 Billion
Merck's weight-loss pill deal: what it means for Eli Lilly
Merck & Co Inc (NYSE: MRK) is in focus this morning after announcing a $2.0 billion deal with Hansoh Pharma. The said agreement wins it rights to HS-10535 – an experimental weight-loss pill (oral) de...
Merck Licenses a Weight-Loss Pill. It's Bad News for Obesity Biotechs.
The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk's dominance in the weight-loss market.
Merck (MRK) Rises Over 1% on Exclusive Licensing Deal with Hansoh Pharma
Merck (MRK) Rises Over 1% on Exclusive Licensing Deal with Hansoh Pharma
What's Going On With Merck Shares Wednesday?
Merck & Company Inc (NYSE: MRK) on Wednesday announced a GLP-1 agreement with Chinese biopharmaceutical company Hansoh Pharma . What Happened: Merck and Hansoh entered into an exclusive global licens...
Merck's (MRK) RSV Antibody BLA Accepted by FDA for Infant Protection
Merck's (MRK) RSV Antibody BLA Accepted by FDA for Infant Protection
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug.
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in payments and royalties on sales.
Merck enters obesity drug race in pact with Chinese pharma Hansoh
Merck (MRK) stock gains as company enters a global licensing deal with Hansoh Pharma to develop an oral obesity drug. Read more here.
Merck signs up to $2 bln obesity drug deal with Chinese biotech Hansoh
U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and commercialize the Chinese biotech's experimental obesity drug.
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license...
Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered i...